Antithrombin III
Antithrombin III is a plasma protein that regulates blood coagulation. Deficiency or dysfunction can increase thrombotic risk and is relevant in bleeding disorders and select therapeutic eligibility assessments.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where Antithrombin III is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors Other · Blood |
|
Approvals defined at the solid tumor level where Antithrombin III is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report Antithrombin III as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports Antithrombin III as part of its biomarker panel.